AMCP Format 4.1 includes new sections describing the evidence needs of HCDMs for unapproved products nearing the end of the product development pipeline, as well as unapproved uses of existing products for which FDA approval is being sought.
AMCP webinar that addressed what is currently being seen in the industry and how to effectively support and continue this early, meaningful, and effective exchange of information for pre-approval products.
AMCP urges justices to affirm federal ERISA law to ensure managed care pharmacy practices continue helping patients access medicines at affordable costs.
To protect managed care pharmacy practices that help patients get the medications they need at a cost they can afford, AMCP submits amicus brief in Rutledge v. The Pharmaceutical Care Management Association (PCMA).
This JMCP article analyzes the cost-effectiveness of brexanolone compared to SSRIs for postpartum depression. Findings indicate that brexanolone may serve as a cost-effective option over SSRIs.
